6-thioguanine nucleotide levels are associated with mucosal healing in patients with Crohn's disease

Inflammatory Bowel Diseases

Volumn 24, Issue 12, 2018, Pages 2621-2627

  Mao, Ren ^a,b   Guo, Jing ^a,c   Luber, Raphael ^d   Chen, Bai Li ^a   He, Yao ^a   Zeng, Zhi Rong ^a   Ben Horin, Shomron ^a,e   Sparrow, Miles P ^d   Roblin, Xavier ^f   Chen, Min Hu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

^c QINGDAO UNIVERSITY   (China)

^d ALFRED HOSPITAL   (Australia)

^e SHEBA MEDICAL CENTER   (Israel)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Crohn's disease; Mucosal healing; Thiopurines

Indexed keywords

MERCAPTOPURINE; THIOGUANOSINE; 6-THIOGUANYLIC ACID; AZATHIOPRINE; BIOLOGICAL MARKER; GUANINE NUCLEOTIDE; IMMUNOSUPPRESSIVE AGENT; NUCLEOTIDE; TIOGUANINE;

ADULT; ARTICLE; AUSTRALIA; CHINA; CONTROLLED STUDY; CORRELATIONAL STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; DISEASE DURATION; ERYTHROCYTE COUNT; FEMALE; FRANCE; HEALTH CENTER; HUMAN; ILEOCOLONOSCOPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY ANALYSIS; WOUND HEALING; ADOLESCENT; BLOOD; CLINICAL TRIAL; DRUG MONITORING; GASTROINTESTINAL ENDOSCOPY; MUCOSA; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AUSTRALIA; AZATHIOPRINE; BIOMARKERS; CHINA; CROHN DISEASE; CROSS-SECTIONAL STUDIES; DRUG MONITORING; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FRANCE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; MALE; MUCOUS MEMBRANE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; ROC CURVE; THIOGUANINE; THIONUCLEOTIDES; YOUNG ADULT;

EID: 85051295760     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1093/IBD/IZY173     Document Type: Article

References (31)

1. Baert F, Moortgat L, Van Assche G, et al; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology. 2010;138:463-468; quiz e10
2. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301
3. Frøslie KF, Jahnsen J, Moum BA, et al; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422
4. Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-a therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550-557.e2
5. Mantzaris GJ, Christidou A, Sfakianakis M, et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis. 2009;15: 375-382
6. Laharie D, Reffet A, Belleannée G, et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Aliment Pharmacol Ther. 2011;33:714-721
7. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738-746
8. Tiede I, Fritz G, Strand S, et al. CD28-dependent rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145
9. Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-939
10. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713
11. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053
12. Moreau AC, Paul S, Del Tedesco E, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis. Inflamm Bowel Dis. 2014;20:464-471
13. Angelberger S, Schaeffeler E, Teml A, et al. Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis. 2013;19:590-598
14. Hindorf U, Lindqvist M, Peterson C, et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut. 2006;55:1423-1431
15. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol. 1996;91:423-433
16. Roblin X, Peyrin-Biroulet L, Biroulet LP, et al. A 6-thioguanine nucleotide threshold level of 400 pmol/8 × 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol. 2008;103:3115-3122
17. Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998;44:551-555
18. Khanna R, Bouguen G, Feagan BG, et al. A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design. Inflamm Bowel Dis. 2014;20:1850-1861
19. Samaan MA, Mosli MH, Sandborn WJ, et al. A systematic review of the measurement of endoscopic healing in ulcerative colitis clinical trials: recommendations and implications for future research. Inflamm Bowel Dis. 2014;20:1465-1471
20. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514
21. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's Disease Activity and Harvey-Bradshaw Indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010;8:357-363
22. Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395
23. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740-746
24. Ohtsuka Y, Arai K, Aoyagi Y, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease. J Gastroenterol Hepatol. 2010;25:1626-1630
25. D'Haens G, Baert F, van Assche G, et al; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667
26. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13:1118-1124.e3
27. Roblin X, Boschetti G, Williet N, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46:142-149
28. Rutgeerts P, Reinisch W, Colombel JF, et al. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016;83:188-197.e1
29. Cote-Daigneault J, Peerani F, Katsanos K, et al. Agreement between Crohn's disease endoscopy severity scores derived from live local, delayed local video-recorded and central readings. Gastroenterology. 2017;152:S209-S210
30. Zhang F, Gao X, Chen M, et al. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease? Ther Drug Monit. 2012;34:695-701
31. Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16:280-285